加载中
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
前收盘价
US$332.07
+US$0.46 · +0.14%
盘后
US$332.07
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
日内区间
当前US$332.07
52周区间
当前US$332.07
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
80
低估
情绪
50
多空交织
风险
22
中等风险
动量
78
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
日内区间
当前US$332.07
52周区间
当前US$332.07
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3.89亿 USD | 2.91亿 USD | 5069.9万 USD | — | — |
| 销货成本 | 2877.3万 USD | 2006.1万 USD | 309.4万 USD | — | — |
| 毛利 | 3.6亿 USD | 2.7亿 USD | 4760.5万 USD | — | — |
| 研究与开发 | 5804.5万 USD | 5357.3万 USD | 4643.1万 USD | 4246.1万 USD | 2788.4万 USD |
| 销售、一般及管理费用 | 1.47亿 USD | 1.14亿 USD | 9840.1万 USD | 7773.5万 USD | 4039.1万 USD |
| 营业费用 | 1.99亿 USD | 2.05亿 USD | 1.57亿 USD | 1.45亿 USD | 6827.5万 USD |
| 利息收入 | 2817.6万 USD | 2966.1万 USD | 2262.4万 USD | 522.1万 USD | 19.7万 USD |
| 利息支出 | — | — | — | — | 149.2万 USD |
| 折旧和摊销 | 655.1万 USD | 671.4万 USD | 500.7万 USD | 405.5万 USD | 276.9万 USD |
| 营业利润 | 1.61亿 USD | 6569.5万 USD | −1.1亿 USD | −1.45亿 USD | −6827.5万 USD |
| 净利润 | 2.05亿 USD | 8915.9万 USD | 1093.2万 USD | −1.4亿 USD | −6957万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.2亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB2.32亿0.12%1853亿 USD0.03%US$288.16-0.46%
iShares Russell 2000 ETFIWM2.26亿0.29%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1.39亿1.40%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Morningstar Small-Cap Growth ETFVBK1.33亿0.29%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF1.1亿0.11%954亿 USD0.05%US$233.52-0.63%
Invesco S&P MidCap Momentum ETFXMMO8937.78万1.25%71.38亿 USD0.34%US$146.5-1.54%
iShares Russell 2000 Growth ETFIWO8014.42万0.58%139.17亿 USD0.24%US$353.71-0.86%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFInvesco S&P MidCap Momentum ETFXMMOiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
